T-cell immunotherapy company Atara Biotherapeutics (Nasdaq: ATRA) closed 41% lower on Friday.
Atara earlier announced receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its Ebvallo (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for patients aged two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen.
According to Atara, the CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for Ebvallo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze